Jose David Piñeiro Ramos

Prof. Dr. Jose David Piñeiro Ramos


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ivan Julian-RochinaIvan Julian-Rochina
Ivan Julian-Rochina
MLMateo López-Moral
Mateo López-Moral
Esther García-MoralesEsther García-Morales
Esther García-Morales
MIMarta Izquierdo-Renau*
Marta Izquierdo-Renau*
JRJose David Piñeiro Ramos
Jose David Piñeiro Ramos
José Luis Lázaro-MartínezJosé Luis Lázaro-Martínez
José Luis Lázaro-Martínez
Diabetic foot syndrome (DFS) is a severe complication affecting millions of people worldwide, yet its clinical management remains predominantly reactive, focusing on established ulcers rather than early preventive measures. Although the role of the cutaneous microbiome in chronic wounds is recognized, longitudinal ecological shifts in the skin of the foot throughout the progression of diabetes mellitus remain underexplored. This structured narrative review evaluates transitional microbial dynamics from intact skin through to active ulceration and explores emerging microbiome-targeted therapies. Based on a structured literature search of PubMed, Scopus, and Web of Science, complemented by citation searching, and a narrative synthesis of 32 selected publications, current evidence suggests that diabetes-associated changes in the cutaneous microbiome involve heterogeneous alterations in microbial diversity and composition, which vary according to microbial community, anatomical location, and clinical status. DFS progression involves a profound ecological collapse, characterized by depletion of protective commensals (e.g., Staphylococcus epidermidis) and the predominance of virulent Staphylococcus aureus lineages alongside Gram-negative anaerobes. Consequently, precision interventions such as topical probiotics, synbiotics, and bacteriophage therapy have substantial potential to disrupt recalcitrant biofilms and reprogram host immunity toward pro-regenerative phenotypes. Ultimately, recognizing the skin as a primary target organ in diabetes mellitus highlights the need to shift DFS management toward a proactive framework. Validating these microbiome-modulating therapies through standardized clinical trials is crucial to restoring host-microbiota symbiosis and ultimately preventing lower-extremity amputations.